What is the study asking?
Using MRI to assess changes associated with clemastine as a potential myelin repair therapy in multiple sclerosis. This is a randomized, double-blind, placebo-controlled study.
Clemastine is being investigated for myelin repair in this study; it is not approved for this use.
Participation at a glance
- Approximate duration
- 6 months
- Minimum visits
- 3 at UCSF
- Typical visit
- 5 hours
Study visit sequence
- Screening
- Month 3
- Month 6
The original lab overview describes two groups: clemastine followed by placebo, or placebo followed by clemastine. Each period lasts three months.
Who may be eligible?
The official listing includes adults ages 18–55 with relapsing-remitting multiple sclerosis and a disease duration of less than 15 years. Additional inclusion and exclusion criteria apply.
Read full criteria on UCSF Clinical Trials
Ask the study team
Use the official UCSF study page to check availability and contact the team.